Use of Topotecan in Patients With Refractory Acute Leukemia

Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00100477

Enrollment

Registered

2004-12-31

Start date

1998-08-31

Completion date

2001-06-30

Last updated

2013-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, Non-Hodgkin's Lymphoma

Keywords

Multiple Myeloma, Lymphoma, Leukemia, Etoposide, Drug Therapy, Clinical Trials

Brief summary

The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).

Detailed description

Interventions

DRUGEtoposide

DRUGTopotecan

DRUGMitozantrone

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

Patients in the following disease categories will be considered eligible for this study: * Any acute leukemia beyond an initial attempt to induce a remission or after relapse * Chronic Myelogenous Leukemia in Blast Phase * Refractory Multiple Myeloma * Refractory non-Hodgkin's and Hodgkin's Lymphoma * Patients must be more than 14 days beyond prior myelotoxic chemotherapy * Several other eligibility criteria apply.

Exclusion criteria

* None

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026